Drug Profile
Latanoprost sustained release implant - Pfizer/EyePoint Pharmaceuticals
Alternative Names: Latanoprost slow release insert - Pfizer/EyePoint Pharmaceuticals; Latanoprost SR insert - Pfizer/EyePoint Pharmaceuticals; Sustained release latanoprost device - Pfizer/EyePoint PharmaceuticalsLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Pfizer; pSivida
- Developer EyePoint Pharmaceuticals; Pfizer; University of Kentucky
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 21 Aug 2019 Discontinued - Phase-I/II for Ocular hypertension in USA (Ophthalmic)
- 21 Aug 2019 Discontinued - Phase-I/II for Open-angle glaucoma in USA (Ophthalmic)
- 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals